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HemoTec and Hemochron activated clotting times will be necessary to
determine xactly what "adequate" anticoagulation is. 
JAMES J. FERGUSON, MD, FACC 
Cardiology Research, MC 1-191 
Texas Heart Institute 
Houston, Texas 77225-0345 
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Congestive Heart Failure and 
Sodium Dichloroacetate 
I recently read with interest he excellent article by Bersin et al. (1) 
reporting on the metabolic and hemodynamic effects of sodium 
dichloroacetate in patients with congestive heart failure. Dichloroac- 
etate, in a dose of 50 mg/kg body weight, resulted in an increase in 
minute work of 12.3% (from 1.38 to 1.55 kg-m/m2), while at the same 
time myocardial oxygen consumption was reduced by 14.5% (from 19.3 
to 16.5 ml/min), resulting in a reported 28% increase in left ventricular 
mechanical efficiency. 
As the authors note, dichloroacetate stimulates pyruvate dehydro- 
genase activity by inhibiting pyruvate dehydrogenase kinase, enhancing 
glycolysis and increasing utilization of lactate, particularly in the 
myocardium. The concomitant inhibition of free fatty acid consump- 
tion leads to a shift of substrate utilization from predominantly free 
fatty acids--the usual preferred energy source of the myocardium--to 
glucose and lactate. The authors relate the improved mechanical 
efficiency of the heart to this shift in metabolic substrate. 
Two points, though, are unclear in this explanation. The authors 
attribute the higher efficiency of glucose to its higher respiratory 
quotient without explaining how the respiratory quotient affects energy 
utilization. Furthermore, they state that glucose and lactate generate 
more adenosine triphosphate (ATP) per mole of substrate (3.0 and 
3.2 mol, respectively) than fatty acids (yielding 2,8 tool of ATP per 
mole of substrate). However, fatty acids yield more ATP than glucose 
per mole of substrate. The complete oxidation of 1 mol of glucose 
yields 36 tool of ATP, not 3.0 tool (2), whereas the oxidation of I mol 
of palmitate, a 16-carbon fatty acid, yields 129 mol of ATP rather than 
2.8 (2). 
It appears more likely that the numbers 2.8 and 3.0 refer instead to 
the ratio, not of ATP to fuel substrate, but of ATP to oxygen 
requirements, a ratio that relates more directly to the issue of energy 
efficiency. For glucose, 6 mol of molecular oxygen (02) are necessary 
to yield 36 mol of ATP, giving an ATP/oxygen ratio (P/O) of 3.0 (2 
atoms of oxygen per molecule). For palmitate, its complete oxidation 
yields 16 mol of CO 2 and 129 tool of ATP (2). The respiratory quotient 
of 0.7 indicates that it requires, 16/0.7 or 22.9 mol of O2 to metabolize 
1 tool of palmitate, yielding a P/O of 129/(22.9 × 2) or 2.8. These 
calculations may explain how the respiratory quotient affects the 
mechanical efficiency of the heart, without directly affecting ATP 
generation, per se. 
One additional finding of this study requires further clarification. 
How does an increase in P/O from 2.8 to 3.0 (or even to 3.2) explain 
a 28% improvement in efficiency? It would seem that another mech- 
anism must be invoked. Is it possible that the metabolic shift caused by 
dichloroacetate, or a direct effect of dichloroacetate itself, could 
change the mechanical properties of the heart, allowing it to perform 
more work for a given level of ATP consumption'?. Perhaps dichloro- 
acetate does have vasodilating properties that effect his improvement 
in efficiency. 
GREGORY M. KOSHKARIAN, MD 
Division of Cardiology 
Georgetown University Medical Center 
Washington, DC 
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Reply 
In response to Koshkarian's letter regarding our article on dichloro- 
acetate in congestive heart failure (1), I have the following reply. 
Koshkarian raises two good points that require further clarification. 
First, he correctly points out that the ratios referred to in the Dis- 
cussion section of the article represent the adenosine triphosphate 
(ATP)/oxygen ratios (P/O ratio), which refer to the number of moles of 
ATP generated per mole of oxygen consumed, not per mole of substrate 
consumed as stated in the article. The respiratory quotients, on the 
other hand, refer to the number of moles of carbon dioxide produced 
per mole of oxygen consumed uring complete oxidation of substrate 
for aerobic respiration. The P/O ratio and the respiratory quotient of 
substrates for aerobic respiration tend to correlate such that substrates 
with the highest P/O ratios (glucose and lactate) tend to have the 
highest respiratory quotients. However, the P/O ratio most directly 
reflects the metabolic efficiency of a substrate. 
Because lactate has the highest P/O ratio (3.2:1), a shift in substrate 
utilization by the myocardium from predominantly free fatty acid 
utilization to lactate consumption should improve cardiac mechanical 
efficiency. However, Koshkarian's second point is that even a complete 
shift from free fatty acid consumption to lactate consumption would 
only be expected to increase cardiac mechanical efficiency by 14%, yet 
a 28% increase in cardiac mechanical efficiency was observed. There- 
fore, the observed change in mechanical efficiency cannot be com- 
pletely explained on the basis of a change in P/O ratios of substrate 
alone. A greater than expected change in mechanical efficiency ob- 
served with dichloroacetate may be explained by other effects that 
substrate and dichloroacetate have on cellular metabolism. 
In isolated rat hearts perfused with solutions containing either 
glucose or free fatty acids (Hexonate), Burkhoff et al. (2) observed a
greater than expected ecrease in myocardial efficiency based on the 
P/O ratios of substrate. Although a 10% reduction in myocardial 
efficiency for excitation-contraction c upling occurred as expected, the 
efficiency of basal metabolic function in the KCI arrested state was 
reduced by nearly 30%. This led Burkhoff et al. to conclude that the 
changes in P/O ratios in switching from glucose to Hexonate could only 
account for a portion of the change of myocardial efficiency measured. 
The difference between the expected and observed efficiencies ap- 
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peared to be due to uncoupling of oxidative phosphorylation byfree 
fatty acids. By uncoupling myocardial oxidative phosphorylation, free 
fatty acids can cause oxygen to be consumed that is not linked to the 
generation of ATP. Also, free fatty acids can stimulate adenosine 
triphosphatase activity and increase ATP consumption that is not 
linked to cellular work; that is, ATP consumption ot used for basal 
metabolism or excitation-contraction c upling. 
Last, in addition to the effects of dichloroacetate on substrate use 
by the myocardium and the effects of substrate use on mechanical 
efficiency, dichloroacetate also stimulates alpha-ketoglutarate dehy- 
drogenase in cardiac muscle by dephosphorylation (3). Increased 
alpha-ketoglutarate d hydrogenase activity could lead to enhanced 
substrate level (TCA cycle) phosphorylation and thereby lead to 
additional ATP production. Although this is speculative, this is yet 
another potential mechanism by which dichloroacetate could improve 
mechanical efficiency above and beyond what would be expected 
simply from a change in P/O ratios of substrate. On the other hand, the 
sodium salt of dichloroacetate does not appear to have vasodilating 
properties. Although the di-isopropyl ammonium salt of dichloroac- 
etate (DIPA) is a vasodilator (4), the vasodilating properties of DIPA 
are probably due to the di-isopropyl ammonium salt of dichloroacetate 
and not due to the dichloroacetate moiety. The sodium salt of 
dichloroacetate has been studied recently in intact dogs, and the results 
from these investigations show little if any direct inotropic or vasodi- 
lating actions of dichloroacetate (R. Wilkins, personal communica- 
tion). The actions of dichloroacetate thus appear to be substantially 
metabolic. 
ROBERT M. BERSIN, MD 
The Sanger Clinic. P.A. 
1001 Blythe Boulevard, Suite 300 
Charlotte, North Carolina 28203 
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CORRECTION 
Mauri F, Maggioni AP, Franzosi MG, De Vita C, Santoro 
E, Santoro L, Giannuzzi P, Tognoni G, for the GISSI-2 
Investigators. A simple electrocardiographic predictor of 
the outcome of patients with acute myocardial infarction 
treated with a thrombolytic agent: a Gruppo Italiano per 
1o Studio della Sopravvivenza nell'Infarto Miocardico 
(GISSI-2)-derived analysis. J Am Coil Cardiol 1994;24: 
600 -7. 
The authors of this article have reported errors in some of the 
data in Table 2. The affected portion of the table with correct 
data is reproduced below. The authors regret the error. 
Table 2. ST Segment Resolution by Demographic, Clinical and Therapeutic Variables 
Decrease inTotal ST 
Segment Elevation ->50% 
Total No. No. of Odds 
of Pts Pts % Ratio 
HR (beats/min) 
<60 1,255 832 66.3 1 
60-100 5,712 3,820 66.9 1.03 
> 100 459 299 65.1 0.95 
Systolic BP (mm Hg) 
<100 386 260 67.4 1 
100-150 5,390 3,594 66.7 0.97 
>150 1,650 1,097 66.5 0.96 
Treatment 
SK 3,660 2,567 70.1 1 
t-PA 3,766 2,384 63.3 0.73 
Heparin 3,703 2,479 66.9 1 
No heparin 3,723 2,472 66.4 0.98 
95% Confidence 
Interval 
0.90-1.17 
0.76-1.19 
0.78 -1.21 
0.76 -1.22 
0.66-0.81 
0.89-1.07 
